Drug Trial Radar · NCT02247349
BMS-986012 in Relapsed/Refractory SCLC
Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Nov 14, 2014
Primary completion
Dec 21, 2022
Study completion Dec 22, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Conditions
- Small Cell Lung Cancer
Interventions
BMS-986012 (anti-fucosyl-GM1)Biological
NivolumabBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: From first dose to 100 days post last dose (Up to 64 months)
- Number of Participants With Serious Adverse Events (SAEs)Time frame: From first dose to 100 days post last dose (Up to 64 months)
- Number of Participants With Adverse Events (AEs) Leading to DiscontinuationTime frame: From first dose to 100 days post last dose (Up to 64 months)
- Number of Participants Who DiedTime frame: From first dose to 100 days post last dose (Up to 64 months)
- Number of Participants With Abnormal Hepatic TestTime frame: From first dose to 100 days post last dose (Up to 64 months)
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Local Institution - 0004
New York, New York
Local Institution - 0001
Durham, North Carolina
Local Institution - 0021
Winston-Salem, North Carolina
Local Institution - 0020
St Leonards, New South Wales, Australia
Local Institution - 0011
Brisbane, Queensland, Australia
Local Institution - 0002
Clayton, Victoria, Australia
Local Institution - 0015
Ghent, Belgium
Local Institution - 0012
Liège, Belgium
Local Institution - 0003
Edmonton, Alberta, Canada
Local Institution - 0017
Halifax, Nova Scotia, Canada
Local Institution - 0019
Hamilton, Ontario, Canada
Local Institution - 0010
London, Ontario, Canada
Local Institution - 0007
Toronto, Ontario, Canada
Local Institution - 0013
Nijmegen, Netherlands
Local Institution - 0009
San Juan, Puerto Rico
Local Institution - 0008
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.